Ensho Health today announced a prospective multi-centre observational study to evaluate the utility of the CA-4F algorithm in clinical care. "We are thrilled to announce the first observational study of a proprietary Ensho screening algorithm" said Dr. Taha Bandukwala, Co-Founder and Chief Medical Officer of Ensho Health.
Transthyretin amyloid cardiomyopathy ("ATTR-CM") is a rare but debilitating cardiac condition characterized by a deposition of misfolded transthyretin amyloid fibrils in the myocardium that results in progressive symptoms of heart failure and increased risk of arrhythmia and conduction abnormalities. The overlap of its symptoms with those of other (and more common) conditions combined with fragmented knowledge about the disease contribute to low awareness, and under- and delayed-diagnosis. The discovery of pharmacological therapy that can slow or halt its progression and favourably affect clinical outcomes has made improved and early detection a priority. Though ATTR-CM can be diagnosed by technetium-99 m pyrophosphate ("Tc-99 m PYP") scintigraphy, determining which patients are suitable for Tc-99 m PYP remains a challenge and universal screening is not practical or economically feasible.
The Study will determine the proportion of patients predicted to have a >10% chance of ATTR-CM on Tc-99 m PYP by CA-4F who are suitable for Tc-99 m PYP in the independent judgement of participating cardiologists, and the positive predictive value of CA-4F of patients in which follow-up investigations were performed.
About Ensho Health
Ensho Health is a health technology company whose mission is to empower healthcare providers to do more with data. It realizes its mission with solutions that improve patient outcomes and facilitate groundbreaking research. It operates clinical data labs that make machine learning and other clinically validated algorithms for early detection and individualized treatment of rare and complex diseases accessible to physicians and their patients, and provide information extraction services for secondary use of data studies with its Apollo aEDC system.
Contact